Completed PHASE2 INTERVENTIONAL NCT00269412

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess The Efficacy and Safety of Three Different Doses (275, 550 AND 1100 MG) of Rifaximin Administered BID For Either Two or Four Weeks in The Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Sponsor: Bausch Health Americas, Inc.

Conditions Irritable Bowel Syndrome

Interventions Rifaximin

Updated 8 times since 2017 Last updated: Nov 21, 2019 Started: Dec 31, 2005 Primary completion: Aug 31, 2007 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Irritable Bowel Syndrome and is currently completed. Bausch Health Americas, Inc. leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2019 — Dec 2019 [monthly]

Completed PHASE2
Jun 2018 — Jun 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bausch Health Americas, Inc.

Data source: Bausch Health Americas, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Anderson, United States , Annapolis, United States , Asheville, United States , Austin, United States , Bellevue, United States , Braintree, United States , Bridgeport, United States , Bristol, United States , Chapel Hill, United States and 51 more locations